Top News

Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype

Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study

Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC

In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib

Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC

Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

more »

FEATURED

IASLC 2018 Coverage

Follow our complete coverage of the International Association for the Study of Lung Cancer 2018 meeting in Toronto, Canada.

Potential Early Plasma Biomarker for RCC

Researchers found that doubling in KIM-1 plasma concentrations were associated with an increased risk of developing of RCC and poorer survival.

Red Flags About Anlotinib’s Efficacy

The VEGFR/EGFR inhibitor anlotinib prolonged PFS and OS in Chinese patients with NSCLC, but additional studies are needed to determine its benefit in other populations.

Ask the Experts: NSCLC

Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with non-small cell lung cancer.

Ask the Experts: STS Clinical Insights

Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.

Ask the Experts: Waldenström Macroglobulinemia

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

By

Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing of RCC and poorer survival.

Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC

Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC

By

The VEGFR/EGFR inhibitor anlotinib prolonged PFS and OS in Chinese patients with NSCLC, but additional studies are needed to determine its benefit in other populations.

Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

By

Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.

BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

By

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

By

A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.

more »

Editorial Advisory Board

 

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Isabel Cunningham, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Mario Sznol, MD

Click here for complete profiles

Fact Sheets

Finding Clinical Trials in Cancer

Finding Clinical Trials in Cancer

By
Managing Immune-Related Adverse Events

Managing Immune-Related Adverse Events

By
more »

Digital Issue



Flip through more digital issues

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs